0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Checkpoint Inhibitors for Treating Cancer Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028
Published Date: September 2022
|
Report Code: QYRE-Auto-25J2388
Home | Market Reports | Health| Health Conditions| Cancer
Global Checkpoint Inhibitors for Treating Cancer Market Insights Forecast to 2026
BUY CHAPTERS

Global Checkpoint Inhibitors for Treating Cancer Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Code: QYRE-Auto-25J2388
Report
September 2022
85 Pages
QYResearch
Region: Global
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Checkpoint Inhibitors for Treating Cancer market is projected to reach US$ 62650 million by 2028 from an estimated US$ 15960 million in 2022, at a CAGR of 25.6% during 2023 and 2028.

The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Checkpoint Inhibitors for Treating Cancer market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitors for Treating Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Bristol-Myers Squibb(BMS)
Merck
Roche
Product Type Insights
Global markets are presented by Checkpoint Inhibitors for Treating Cancer type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Checkpoint Inhibitors for Treating Cancer are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Checkpoint Inhibitors for Treating Cancer Segment by Type

PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Checkpoint Inhibitors for Treating Cancer market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Checkpoint Inhibitors for Treating Cancer market.

Checkpoint Inhibitors for Treating Cancer Segment by Application

Melanoma Treatment
Bladder Cancer Treatment
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Checkpoint Inhibitors for Treating Cancer market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Checkpoint Inhibitors for Treating Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Checkpoint Inhibitors for Treating Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Checkpoint Inhibitors for Treating Cancer industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Checkpoint Inhibitors for Treating Cancer

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution

1 Study Coverage
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2017-2028
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2017-2028
2.2 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2022 Versus 2028
2.3 Checkpoint Inhibitors for Treating Cancer Sales by Region (2017-2028)
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2017-2022
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2023-2028)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2017-2028)
2.4 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region (2023-2028)
2.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2017-2022
2.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2023-2028)
2.4.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2017-2028)
3 Global Checkpoint Inhibitors for Treating Cancer by Manufacturers
3.1 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Sales
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2017-2022)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer (2017-2022)
3.2 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2017-2022)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2017-2022)
3.3 Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturer (2017-2022)
3.4 Competitive Landscape
3.4.1 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
3.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.4.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Type
3.5.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
3.5.3 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Bristol-Myers Squibb(BMS)
4.1.1 Bristol-Myers Squibb(BMS) Corporation Information
4.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview
4.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
4.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2017-2022)
4.1.5 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Product in 2021
4.1.6 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Application in 2021
4.1.7 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2021
4.1.8 Bristol-Myers Squibb(BMS) Recent Developments
4.2 Merck
4.2.1 Merck Corporation Information
4.2.2 Merck Description, Business Overview
4.2.3 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
4.2.4 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2017-2022)
4.2.5 Merck Checkpoint Inhibitors for Treating Cancer Sales by Product in 2021
4.2.6 Merck Checkpoint Inhibitors for Treating Cancer Sales by Application in 2021
4.2.7 Merck Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2021
4.2.8 Merck Recent Developments
4.3 Roche
4.3.1 Roche Corporation Information
4.3.2 Roche Description, Business Overview
4.3.3 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
4.3.4 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2017-2022)
4.3.5 Roche Checkpoint Inhibitors for Treating Cancer Sales by Product in 2021
4.3.6 Roche Checkpoint Inhibitors for Treating Cancer Sales by Application in 2021
4.3.7 Roche Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2021
4.3.8 Roche Recent Developments
5 Breakdown Data by Type
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2028)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2023-2028)
5.1.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2028)
5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2017-2028)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2017-2022)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2023-2028)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2017-2028)
5.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2028)
6.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022)
6.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2023-2028)
6.1.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2028)
6.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2017-2028)
6.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2017-2022)
6.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2023-2028)
6.2.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2017-2028)
6.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2017-2028)
7 North America
7.1 North America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2017-2028
7.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
7.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2028)
7.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2028)
7.3 North America Checkpoint Inhibitors for Treating Cancer Sales by Type
7.4 North America Checkpoint Inhibitors for Treating Cancer Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
8.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2017-2028)
8.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2017-2028)
8.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type
8.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application
9 Europe
9.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2017-2028
9.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
9.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2028)
9.2.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2028)
9.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Type
9.4 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application
10 Latin America
10.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2017-2028
10.2 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
10.2.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2028)
10.2.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2028)
10.3 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type
10.4 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
11.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2028)
11.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2028)
11.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type
11.4 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Checkpoint Inhibitors for Treating Cancer Supply Chain Analysis
12.2 Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
12.3 Checkpoint Inhibitors for Treating Cancer Clients Analysis
12.4 Checkpoint Inhibitors for Treating Cancer Sales Channel and Sales Model Analysis
12.4.1 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Checkpoint Inhibitors for Treating Cancer Distributors
13 Market Dynamics
13.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
13.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
13.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
13.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
13.5 Porter’s Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Major Manufacturers of PD-1 Inhibitors
    Table 3. Major Manufacturers of PD-L1 Inhibitors
    Table 4. Major Manufacturers of CTLA-4 Inhibitors
    Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million): 2021 VS 2022 VS 2028
    Table 7. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2017-2022) & (K Units)
    Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2023-2028) & (K Units)
    Table 9. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2017-2022) & (US$ Million)
    Table 10. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 11. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2017-2022) & (K Units)
    Table 12. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer (2017-2022)
    Table 13. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2017-2022) & (US$ Million)
    Table 14. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2017-2022)
    Table 15. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2017-2022) & (USD/Unit)
    Table 16. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2021
    Table 17. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) & (2017-2022)
    Table 18. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2021)
    Table 19. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
    Table 20. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
    Table 21. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
    Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 23. Bristol-Myers Squibb(BMS) Corporation Information
    Table 24. Bristol-Myers Squibb(BMS) Description and Business Overview
    Table 25. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 26. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
    Table 27. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2021
    Table 28. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2021
    Table 29. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2021
    Table 30. Bristol-Myers Squibb(BMS) Recent Development
    Table 31. Merck Corporation Information
    Table 32. Merck Description and Business Overview
    Table 33. Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 34. Merck Checkpoint Inhibitors for Treating Cancer Product
    Table 35. Merck Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2021
    Table 36. Merck Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2021
    Table 37. Merck Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2021
    Table 38. Merck Recent Development
    Table 39. Roche Corporation Information
    Table 40. Roche Description and Business Overview
    Table 41. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 42. Roche Checkpoint Inhibitors for Treating Cancer Product
    Table 43. Roche Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2021
    Table 44. Roche Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2021
    Table 45. Roche Checkpoint Inhibitors for Treating Cancer Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2021
    Table 46. Roche Recent Development
    Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 48. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2023-2028) & (K Units)
    Table 49. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2017-2022) & (US$ Million)
    Table 50. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 51. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 52. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2023-2028) & (K Units)
    Table 53. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2017-2022) & (US$ Million)
    Table 54. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 55. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2022) & (K Units)
    Table 56. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2023-2028) & (K Units)
    Table 57. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2023-2028) & (US$ Million)
    Table 59. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 60. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 61. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2017-2022) & (K Units)
    Table 62. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2023-2028) & (K Units)
    Table 63. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2017-2028) & (US$ Million)
    Table 64. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2023-2028) & (US$ Million)
    Table 65. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 66. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 67. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2022) & (K Units)
    Table 68. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2023-2028) & (K Units)
    Table 69. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 72. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 73. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2022) & (K Units)
    Table 74. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2023-2028) & (K Units)
    Table 75. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2022) & (US$ Million)
    Table 76. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2023-2028) & (US$ Million)
    Table 77. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 78. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 79. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2017-2022) & (K Units)
    Table 80. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2023-2028) & (K Units)
    Table 81. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2017-2022) & (US$ Million)
    Table 82. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2023-2028) & (US$ Million)
    Table 83. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2017-2022) & (K Units)
    Table 84. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2017-2022) & (K Units)
    Table 85. Checkpoint Inhibitors for Treating Cancer Key Raw Materials, Industry Status and Trend
    Table 86. Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
    Table 87. Checkpoint Inhibitors for Treating Cancer Clients Status and Trend
    Table 88. Checkpoint Inhibitors for Treating Cancer Typical Clients
    Table 89. Checkpoint Inhibitors for Treating Cancer Distributors
    Table 90. Checkpoint Inhibitors for Treating Cancer Market Trends
    Table 91. Checkpoint Inhibitors for Treating Cancer Market Drivers
    Table 92. Checkpoint Inhibitors for Treating Cancer Market Challenges
    Table 93. Checkpoint Inhibitors for Treating Cancer Market Restraints
    Table 94. Research Programs/Design for This Report
    Table 95. Key Data Information from Secondary Sources
    Table 96. Key Data Information from Primary Sources
List of Figures
    Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
    Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2021 & 2028
    Figure 3. PD-1 Inhibitors Product Picture
    Figure 4. PD-L1 Inhibitors Product Picture
    Figure 5. CTLA-4 Inhibitors Product Picture
    Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2021 & 2028
    Figure 7. Melanoma Treatment Examples
    Figure 8. Bladder Cancer Treatment Examples
    Figure 9. Other Examples
    Figure 10. Checkpoint Inhibitors for Treating Cancer Report Years Considered
    Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market Size 2017-2028 (US$ Million)
    Figure 13. Global Checkpoint Inhibitors for Treating Cancer Sales 2017-2028 (K Units)
    Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2022 Versus 2028
    Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2017-2028)
    Figure 16. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2017-2028)
    Figure 17. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2021
    Figure 18. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 19. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2017-2028)
    Figure 20. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2017-2028)
    Figure 21. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2017-2022) & (USD/Unit)
    Figure 22. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2017-2028)
    Figure 23. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2017-2028)
    Figure 24. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2017-2022) & (USD/Unit)
    Figure 25. North America Checkpoint Inhibitors for Treating Cancer Revenue 2017-2028 (US$ Million)
    Figure 26. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2022)
    Figure 27. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2022)
    Figure 28. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue 2017-2028 (US$ Million)
    Figure 29. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2017-2028)
    Figure 30. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2017-2028)
    Figure 31. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2022)
    Figure 32. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2022)
    Figure 33. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2017-2028 (US$ Million)
    Figure 34. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2017-2028)
    Figure 35. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2017-2028)
    Figure 36. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2022)
    Figure 37. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2022)
    Figure 38. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2017-2028 (US$ Million)
    Figure 39. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2017-2028)
    Figure 40. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2017-2022)
    Figure 41. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2022)
    Figure 42. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2022)
    Figure 43. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2017-2028 (US$ Million)
    Figure 44. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2017-2028)
    Figure 45. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2017-2028)
    Figure 46. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2017-2022)
    Figure 47. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2017-2022)
    Figure 48. Checkpoint Inhibitors for Treating Cancer Supply Chain (Upstream and Downstream Market)
    Figure 49. Global Production Market Share of Checkpoint Inhibitors for Treating Cancer Raw Materials by Region in 2021
    Figure 50. Checkpoint Inhibitors for Treating Cancer Distribution Channels
    Figure 51. Global Checkpoint Inhibitors for Treating Cancer Percentage 2017-2028: Indirect Sales VS Direct Sales
    Figure 52. Global Checkpoint Inhibitors for Treating Cancer Percentage 2017-2028: Online Sales VS Offline Sales
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$5900
This license allows only one user to access the PDF.

Electronic (PDF)
$8850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$11800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Kidney Cancer Market Insights Forecast to 2028
Global Kidney Cancer Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-38R2107
Thu Oct 27 00:00:00 UTC 2022

Add to Cart

Global Gastrointestinal Stromal Tumor Market Insights and Forecast to 2028
Global Gastrointestinal Stromal Tumor Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-3H3477
Fri Oct 21 00:00:00 UTC 2022

Add to Cart

Global Gynecological Cancers Market Insights and Forecast to 2028
Global Gynecological Cancers Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-13K6204
Fri Oct 21 00:00:00 UTC 2022

Add to Cart

Global Antiangiogenic Agent Market Research Report 2022
Global Antiangiogenic Agent Market Research Report 2022

120 Pages
Type: Report
Code: QYRE-Auto-30H12054
Fri Oct 21 00:00:00 UTC 2022

Add to Cart